Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Imatinib Mesylate and Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer

NCT00161213 is registered in ClinicalTrials.gov with University of Medicine and Dentistry of New Jersey as lead sponsor.

NCT NCT00161213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00161213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Imatinib Mesylate and Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer
Lead sponsor
University of Medicine and Dentistry of New Jersey
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
October 31, 2010
Enrollment
44 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer